Psychometric Validation and Determination of the Minimal Clinically Important Difference for Bronchiectasis Health Questionnaire in Adults with Bronchiectasis.
{"title":"Psychometric Validation and Determination of the Minimal Clinically Important Difference for Bronchiectasis Health Questionnaire in Adults with Bronchiectasis.","authors":"Jin-Fu Xu, Surinder S Birring, Yuan-Yuan Li, Ming-Xin Shi, Hai-Wen Lu, Shuyi Gu, Jie-Ming Qu, Yong-Hua Gao, Wei-Jie Guan, Nan-Shan Zhong","doi":"10.1513/AnnalsATS.202407-751OC","DOIUrl":null,"url":null,"abstract":"<p><strong>Rationale: </strong>The Bronchiectasis Health Questionnaire (BHQ) is a concise, self-administered and disease-specific instrument for measuring health-related quality-of-life (HRQoL) in bronchiectasis.</p><p><strong>Objectives: </strong>To investigate the psychometric properties of simplified Mandarin BHQ and determine the minimum clinically important difference (MCID) as a reliable clinical endpoint for assessing the efficacy of bronchiectasis treatments.</p><p><strong>Methods: </strong>A longitudinal, randomized controlled trial cohort of 357 patients treated with tobramycin inhalation solution or saline inhalation for Pseudomonas aeruginosa infection, along with a cross-sectional observational cohort including 436 patients with bronchiectasis were analyzed. Psychometric analyses encompassed convergent validity, known-groups validity, internal consistency, test-retest reliability, and responsiveness. Both anchor-based and distribution-based approaches were utilized to calculate the MCID for therapeutic response.</p><p><strong>Results: </strong>There were significant positive correlations between BHQ scores and the Quality of Life - Bronchiectasis Respiratory Symptom Scale (QoL-B-RSS), with correlation coefficient 0.698 in the trial cohort and 0.567 in the clinical cohort (both P<0.0001). Known-groups validity indicated significant differences in BHQ scores stratified by baseline Bronchiectasis Severity Index. BHQ scores correlated modestly with both FEV1% predicted and exacerbation frequency within the previous year. In the trial cohort, BHQ demonstrated excellent internal consistency (Cronbach's alpha: 0.893) and test-retest reliability (intraclass correlation coefficient: 0.853). An 8-point improvement in QoL-B-RSS corresponded to a mean increase of 5.49 points in BHQ scores after 4-week treatment. The MCID for BHQ was consistently 3 points.</p><p><strong>Conclusions: </strong>The BHQ (MCID: 3 points) represents a clinically meaningful tool for evaluating therapeutic intervention outcomes and patient-centered outcomes in patients with bronchiectasis.</p>","PeriodicalId":93876,"journal":{"name":"Annals of the American Thoracic Society","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of the American Thoracic Society","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1513/AnnalsATS.202407-751OC","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Rationale: The Bronchiectasis Health Questionnaire (BHQ) is a concise, self-administered and disease-specific instrument for measuring health-related quality-of-life (HRQoL) in bronchiectasis.
Objectives: To investigate the psychometric properties of simplified Mandarin BHQ and determine the minimum clinically important difference (MCID) as a reliable clinical endpoint for assessing the efficacy of bronchiectasis treatments.
Methods: A longitudinal, randomized controlled trial cohort of 357 patients treated with tobramycin inhalation solution or saline inhalation for Pseudomonas aeruginosa infection, along with a cross-sectional observational cohort including 436 patients with bronchiectasis were analyzed. Psychometric analyses encompassed convergent validity, known-groups validity, internal consistency, test-retest reliability, and responsiveness. Both anchor-based and distribution-based approaches were utilized to calculate the MCID for therapeutic response.
Results: There were significant positive correlations between BHQ scores and the Quality of Life - Bronchiectasis Respiratory Symptom Scale (QoL-B-RSS), with correlation coefficient 0.698 in the trial cohort and 0.567 in the clinical cohort (both P<0.0001). Known-groups validity indicated significant differences in BHQ scores stratified by baseline Bronchiectasis Severity Index. BHQ scores correlated modestly with both FEV1% predicted and exacerbation frequency within the previous year. In the trial cohort, BHQ demonstrated excellent internal consistency (Cronbach's alpha: 0.893) and test-retest reliability (intraclass correlation coefficient: 0.853). An 8-point improvement in QoL-B-RSS corresponded to a mean increase of 5.49 points in BHQ scores after 4-week treatment. The MCID for BHQ was consistently 3 points.
Conclusions: The BHQ (MCID: 3 points) represents a clinically meaningful tool for evaluating therapeutic intervention outcomes and patient-centered outcomes in patients with bronchiectasis.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
